Cooley

Rena Kaminsky

Special Counsel

rkaminsky@cooley.com

+1 650 843 5160

Palo Alto

Life Sciences and Healthcare
Life Sciences Corporate Partnering and Licensing
Biotechnology

Rena Kaminsky represents biotechnology, medical device, and other public and private life sciences companies in a wide range of intellectual property and commercial transactions, including corporate partnering, licenses, research and development collaborations, and manufacturing and supply arrangements.

Rena's recent transactions include:

- Neurocrine Biosciences in its gene therapy collaboration with Voyager Therapeutics valued at $165 million upfront and up to $1.7 billion in milestone payments
- iNtRON Biotechnology in its license agreement with Roivant Sciences for endolysin biologics for treating infectious diseases
- Fate Therapeutics in its strategic collaboration with ONO Pharmaceutical for CAR-T cell cancer immunotherapies
- Arena Pharmaceuticals in its license agreement with Everest Medicines for China, Taiwan and South Korea valued at up to $212 million
- Calithera Biosciences in two clinical trial collaborations with Pfizer
- HanAll BioPharma in its $500 million license agreement with Roivant Sciences
- HanAll BioPharma in its collaboration and license agreement with Harbour BioMed for $81 million upfront and potential milestones
- Molecular Partners AG in its collaboration and option agreement with Allergan for multi-target discovery programs valued up to $1.4 billion
- Sangamo Therapeutics in its collaboration with Kite/Gilead to develop next-generation engineered cell therapies for the treatment of cancer for $150 million upfront, up to $3 billion in milestones and tiered royalties.
- Sangamo Therapeutics in its collaboration and license agreement with Pfizer to develop and commercialize gene therapy programs for hemophilia A for $70 million upfront, potential milestones up to $475 million and tiered double digit royalties.
- Calithera Biosciences in its collaboration with Incyte for the development and commercialization of CB-1158, a small molecule arginase inhibitor, including an upfront payment to Calithera of $45 million, equity investment of $8 million, milestones, profit-share in the US, and milestones and other royalties ex-US
- Takeda in its collaboration agreement with NuBiyota to develop and commercialize microbiome

therapeutics for GI indications

Education

Stanford Law School JD, with distinction, Order of the Coif, 2006

Yale University BS, summa cum laude, Phi Beta Kappa, 1992

Admissions & Credentials

California

Registered to practice before the United States Patent and Trademark Office (USPTO)

Memberships & Affiliations

American Bar Association (ABA)